Ftse Mib
33.746,66
-1,60%
DAX
17.932,17
-1,10%
S&P 500
5.018,39
-0,34%
NASDAQ Composite
15.605,48
-0,33%
Bitcoin
58.262,38
0,04%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Poseida Therapeutics Inc (PSTX) Poseida Therapeutics Inc (PSTX) Notizie

Poseida Therapeutics Inc

PSTX
2,74
0,32 (13,22%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 00:31:32
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
01/5/202415:00PRNUSAstellas and Poseida Therapeutics Enter Into Research..
18/4/202414:00PRNUSPoseida Therapeutics Announces Strong Lineup of..
17/4/202415:00PRNUSPoseida Therapeutics Hosts Gene Therapy R&D Day Highlighting..
08/4/202418:00PRNUSPoseida Therapeutics Presents New Phase 1 Data at AACR 2024..
01/4/202422:05PRNUSPoseida Therapeutics Announces Inducement Grant Under Nasdaq..
25/3/202421:05PRNUSPoseida Therapeutics Appoints Syed Rizvi, M.D., as Chief..
19/3/202421:05PRNUSPoseida Therapeutics to Present at H.C. Wainwright 2nd..
13/3/202421:05PRNUSPoseida Therapeutics Announces FDA Orphan Drug Designation..
07/3/202422:07PRNUSPoseida Therapeutics Provides Updates and Financial Results..
07/3/202422:05EDGAR2Form 8-K - Current report
04/3/202423:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202423:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:05PRNUSPoseida Therapeutics Announces Inducement Grant Under Nasdaq..
08/2/202422:10EDGAR2Form S-8 - Securities to be offered to employees in employee..
04/1/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:01EDGAR2Form 8-K - Current report
04/1/202414:00PRNUSPoseida Therapeutics Highlights Recent Progress, Strategic..
11/12/202316:31DJNPoseida Therapeutics Shares Climb on Positive Data for Blood..
11/12/202312:06EDGAR2Form 8-K - Current report
10/12/202318:00PRNUSPoseida Therapeutics Presents Positive Early Results from..
09/11/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:05EDGAR2Form 8-K - Current report
09/11/202322:05PRNUSPoseida Therapeutics Provides Updates and Financial Results..
07/11/202314:00PRNUSPoseida Therapeutics to Present at Two Upcoming Investor..
02/11/202314:01PRNUSPoseida Therapeutics to Present at the 65th ASH Annual..
09/10/202322:30PRNUSPoseida Therapeutics Announces Leadership Transition
05/9/202314:00PRNUSPoseida Therapeutics to Present at Two Upcoming Investor..
14/8/202322:41EDGAR2Form SC 13D - General statement of acquisition of beneficial..
11/8/202322:48EDGAR2Form D - Notice of Exempt Offering of Securities
08/8/202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202322:06EDGAR2Form 8-K - Current report
08/8/202322:05PRNUSPoseida Therapeutics Provides Financial Results for the..
07/8/202316:41DJNPoseida Therapeutics Shares Leap on Astellas Investments
07/8/202315:58DJNPoseida Therapeutics in $50 Million Investment Deal With..
07/8/202315:01EDGAR2Form 8-K - Current report
07/8/202315:01PRNUSPoseida Therapeutics Announces Strategic Investment by..
07/8/202315:00PRNUSAstellas and Poseida Therapeutics Announce Strategic..
05/7/202314:00PRNUSPoseida Therapeutics Announces FDA Clearance of..
26/6/202314:00PRNUSPoseida Therapeutics to Join Russell 3000® and Russell 2000®..
01/6/202314:00PRNUSPoseida Therapeutics Announces Virtual 2023 Annual Meeting..
23/5/202314:00PRNUSPoseida Therapeutics to Present at Stifel 2023 Tailoring..
22/5/202314:00PRNUSPoseida Therapeutics to Present at 31st Congress of the..
18/5/202314:00PRNUSPoseida Therapeutics Presents Encouraging Preclinical Data..
09/5/202322:05PRNUSPoseida Therapeutics Provides Updates and Financial Results..
Apertura: 2,69 Min: 2,685 Max: 3,00
Chiusura: 2,42

La tua Cronologia

NASDAQ
PSTX
Poseida Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network